Gellan-based scleral implants of indomethacin: In vitro and in vivo evaluation

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 11, Issue 6, 2004, Pages 371-379

  Balasubramaniam, J ^a,c   Kumar, M Thilek ^a   Pandit, J K ^a   Kant, Shri ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

Gellan; In vitro and in vivo evaluation; Indomethacin; Scleral implants

Indexed keywords

GELLAN; GELRITE; GLYCEROL; INDOMETACIN; MACROGOL 200; MACROGOL 400; PLASTICIZER; PROPYLENE GLYCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DELAYED DRUG RELEASE; DIFFUSION COEFFICIENT; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG IMPLANT; DRUG MANUFACTURE; DRUG RELEASE; FILM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; PHARMACODYNAMICS; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; SCLERA; TREATMENT OUTCOME; UVEITIS; WATER CONTENT;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; INDOMETHACIN; POLYSACCHARIDES, BACTERIAL; RABBITS; SCLERA; UVEITIS;

EID: 9644274085     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/10717540490884787     Document Type: Article

References (35)

1. Al-Musa, S., Abu Fara, D., and Badwan, A. A. 1999. Evaluation of parameters involved in preparation and release of drug loaded in cross-linked matrices of alginate. J. Contr. Rel. 57:223-232.
2. + Gellan polymer morphology during sol-gel transition. Biopolymers 54:195-210.
3. Balasubramaniam, J., and Pandit, J. K. 2002. In vitro characterization of a non-degradable scleral implant of indomethacin for prolonged ocular delivery. Acta Pharm. 52:181-188.
4. Balasubramaniam, J., Thilek Kumar, M., Pandit, J. K., and Kant, S. 2001. In vitro and in vivo characterization of scleral implants of indomethacin. Pharmazie 56:793-799.
5. Baum, J., Peyman, G. A., and Barza, M. 1982. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis III: consensus. Sum. Ophthalmol. 26:204-206.
6. Blagogevic, M., Parunovic, J., Nicolic, J., and Mladenovic, V. 1970. L'aspect clinique et immunitaire des iridocyclites rhumatis mates. Bull. Soc. Ophthalmol. Fr. 83:71-16.
7. Cantrill, W. H., Henry, K., Merloe, N. H., Knobloch, W. H., Ramsey, R. C., and Balfour, H. H. 1989. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long-term results. Ophthalmology 96:367-374.
8. Cocherau-Massin, I., Lehoang, P., Iautier-Frau, M., Zazon, L., and Robinet, M. 1991. Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 98:1348-1355.
9. Gilman, A. G. 1990. The Pharmacological Basis of Therapeutics. New York: Permagon Press.
10. Guo, J. H. 1994. An investigation into the formation of plasticizer channels in plasticized polymer films. Drug Dev. Ind. Pharm. 20:1883-1893.
11. Heineman, M. H. 1989. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch. Ophthalmol. 107:1767-1772.
12. Henderly, D. E., Freeman, W. R., Causey, D. M., and Rao, N. A. 1987. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94:425-434.
13. Jabs, D. A., Newman, C., de Bustors, S., and Polk, B. F. 1987. Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94:824-830.
14. Kamath, K. R., and Park, K. 1993. Biodegradable hydrogels in drug delivery. Adv. Drug Del. Rev. 11:59-84.
15. Kang, K. S., Veeder, G. T., and Cottrell, I. W. 1983. Gellan gum, a new polysaccharide. Prog. Indust. Microbiol. 18:231-253.
16. Kunou, N., Ogura, Y., Hashizoe, M., Honda, Y., Hyon, S. H., and Ikada, Y. 1995. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbit eye. J. Contr. Rel. 37:143-150.
17. Leopold, I. H., and Gaster, R. N. 1990. Ocular inflammation and anti-inflammatory drugs in the cornea. In ed. Kaufman, H. E., Barren, B. A., McDonald, M. B., and Waltman, S. R., eds. New York: Churchill Livingstone.
18. Li, J., Kamath, K., and Diwedi, C. 2001. Gellan film as implant for insulin delivery. Biomat. Appl. 15:321-343.
19. Lurhuma, A. Z., Cambiaso, C. L., Masson, P. L., and Heremans, J. F. 1976. Deletion of circulating antigen-antibody complexes by their inhibitory effect on the agglutination of IgG coated particles by rheumatoid factor or clq. Clin. Exp. Immunol. 25:212-226.
20. Maurice, D. M., and Mishima, S. 1984. Ocular pharmacokinetics. In ed. Pharmacology of the Eye Sears, M. L. 19-116. New York: Springer-Verlag.
21. O'Connor, G. R. 1983. Behcet's disease In Ktein, E. A., 1990 Symposium on Medical and Surgical-Diseases of the Retina and Vitreous ed. St. Louis: C. V. Mosby.
22. Pandit, J. K., and Barat, R. 2001. Novel systems for the treatment of cytomegalovirus retinitis in immuno-compromised patients. In Jain, N. K. (Eds), Advances in Controlled and Novel Drug Delivery, ed. Jain N. K., 307-316. New Delhi: CBS Publishers.
23. Peyman, G. A., and Schulman, J. A. 1989. Intravitreal drug therapy. Jpn. J. Ophthalmol. 33:392-404.
24. Rozier, A., Mazuel, C., Grove, J., and Plaronner, B. 1989. Gelrite: a novel, ion activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int. J. Pharm. 57:163-168.
25. Sanderson, G. R. 1990. Gellan gum. In ed. Harris, P. 201-233. (Eds) London and New York: Elseiver Applied Science.
26. Sanzgiri, Y. D., Maschi, V., and Crescenzi, L. 1993. Gellan-based system for ophthalmic sustained delivery of methyl prednisolone. J. Cont. Rel. 26:195-201.
27. Simon, B. 1992. Structure and rheology of gelatin gels:recent progress. Polymer 33 (12):2622-2627.
28. Stein, A. L., Taylor, D. M., Dalburg, L. A., and Losentino, R. T. 1981. Pseudophacic cystoid maculopathy: a study of 50 cases. Ophthalmology 88:942-946.
29. Thanoo, B. C., Sunny, M. C., and Jayakrishnan, A. 1992. A cross-linked chitosan microspheres: preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J. Pharm. Pharmacol. 44:283-286.
30. The UCLA CMV retinopathy study group, Holland, G. N., Sakamoto, M. J., Hardy, D., Sidikano, Y., Krieger, A. E., Frenkel, L. M. 1986. Treatment of cytomegalovirus retinopathy in patients with acquired immuno deficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxy methyl) ethoxy methyl] guanine. Arch. Ophthalmol. 104:1794-1800.
31. Thilek Kumar, M., Pandit, J. K. and Balasubramaniam, J. 2001. Novel therapeutic approaches for uveitis and retinitis. J. Pharm. Pharmaceut. Sci. 4(3):248-254.
32. Thilek Kumar, M., Rajeswari, C., Balasubramaniam, J., and Pandit, J. K. 2003. In vitro and in vivo characterization of scleral implant of indomethacin: role of plasticizer and cross-linking time. Drug Del. 10:1-7.
33. Ussery, F. M., Gibson, S. R., Conklin, R. H., Pilot, D. F., Stool, E. W., and Conklin, A. J. 1988. Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis. Ophthalmology 95:640-648.
34. Vazquez, M. J., Perez-Marcos, B., Gomez-Amoza, J. L., Martinez-Pacheco, R., Souto, C., and Concheiro, A. 1992. Influence of technological variables on release of drugs from hydrophilic matrices. Drug Dev. Ind. Pharm. 18:1355-1375.
35. Velez, G., and Whitcup, S. M. 1999. New developments in sustained release drug delivery for the treatment of intraocular disease. Br. J. Ophthalmol. 83:1225-1229.